Abstract 4228: PRISM cancer cell viability profiling enables insights into clinical candidate target selectivity: A case study revealing the most selective PRMT5 inhibitors for cancers with MTAP loss

Authors: Laura Doherty, Colleen Harrington, Mustafa Kocak, Anthony Fazio, John Davis, Emily Reeves, Rachael Barry, Claudine Mapa, Dennie Frederick, Alvin Kalathungal, Jillian Eskra, Tenzin Sangpo, Melissa Ronan, William Sellers, Matthew Rees, Jennifer Roth

Published: 2025-04-21

DOI: 10.1158/1538-7445.am2025-4228

Source: Full article